Slower intravenous tramadol administration can prevent nausea and vomiting and predict postoperative nausea and vomiting: a randomized controlled trial
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Slow intravenous administration of tramadol (1.5 mg/kg) over 3 minutes, compared to 1 minute, significantly reduces preoperative nausea and vomiting. This finding is crucial for managing postoperative nausea and vomiting risks in patients receiving tramadol analgesia.
Area Of Science
- Anesthesiology
- Pharmacology
- Clinical Pain Management
Background
- Nausea and vomiting are frequent complications associated with tramadol analgesia.
- Intravenous tramadol administration is a common practice for pain management.
- Understanding risk factors for tramadol-induced nausea and vomiting is critical for patient safety.
Purpose Of The Study
- To evaluate the risk of nausea and vomiting associated with different intravenous administration rates of tramadol.
- To determine the relationship between preoperative nausea and vomiting and postoperative outcomes.
- To identify optimal administration protocols for intravenous tramadol to minimize side effects.
Main Methods
- A study involving 315 patients undergoing elective surgery who received pre-analgesia.
- Patients were stratified into high, medium, and low-risk groups based on the Apfel score for nausea and vomiting.
- Intravenous tramadol (1.5 mg/kg) was administered over 1, 2, or 3 minutes prior to anesthesia induction, with observations for preoperative nausea and vomiting within 10 minutes.
Main Results
- In the low-risk group, slower administration (3 minutes) resulted in significantly lower postoperative nausea and vomiting scores compared to rapid administration (1 minute).
- The incidence of preoperative nausea and vomiting after tramadol administration was significantly linked to postoperative nausea and vomiting.
- Preoperative nausea and vomiting following 1-minute and 3-minute administration were identified as independent risk factors for postoperative nausea and vomiting.
Conclusions
- Slow intravenous administration of tramadol over 3 minutes is recommended to reduce the incidence of nausea and vomiting.
- Clinicians should consider slow tramadol infusion to improve patient outcomes and minimize side effects.
- This practice is suggested for routine adoption in clinical pain management.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.